Senior professionals and middle managers are experiencing increased burnout and stress, leading to higher alcohol consumption, and there is a need for better support and resources for mental health and addiction treatment in Australia, according to Ruth Limkin, Founder of The Banyans and Chief Development Officer at parent Sana Health Group.
“Burnout and stress is likely due to the immense pressure and crisis management they have been facing, leading to a need for self-care. Middle managers are more likely to take out work stress on their family, so it’s important to have conversations and provide support.”, says Ms Limkin.
Alcohol consumption has increased significantly during COVID, with one in three senior managers and 50% of middle managers and the wider workforce drinking more when stressed, including day drinking while working from home.
Australian Health Journal spoke with Ms Limkin, on the Sana Health treatment centres in Sunshine Coast, Brisbane and Byron Bay having different client types, with some people self-medicating undiagnosed mental health conditions, and it can be confusing for them to find help.
Sana Health Group offers a wide range of practitioners and treatment programs for mental health, addiction, and eating disorders in Australia. However Ms Limkin raises the issue that in primary health GPs need more funding and support for better patient care and understanding of available options.
“The environment where you receive care affects the care you receive, and it’s important to help patients navigate the healthcare system and understand their treatment options.”, says Ms Limkin.
According to Ms Limkin, healthcare professionals need more resources and time to collaborate with patients and provide holistic care for better results in the Australian health system.
Practitioners need time to work collaboratively with patients using evidence-based research and at Sana Healthcare centres, a more holistic approach to wellbeing is taken to deliver better results.
-
Reflecting on a pivotal year for pharmacy
Dr. Kate Wang, a Senior Lecturer in Pharmacy at RMIT University and Adjunct Senior Lecturer, University of Western Australia, has over a decade of experience in both hospital and community pharmacy settings.
Dr Wang spoke to Australian Health Journal on some of the key topics in 2024 that have been pivotal as a pharmacist, academic and researcher for the pharmacy profession.
-
Pathology technology at a crossroads
The CEO of Pathology Technology Australia, Dean Whiting spoke with Australian Health Journal about the following:
– Pathology Technology Australia’s key priorities in the coming years
– Current local capability in pathology technology compared to other countries
– How the health system supports change and adoption of pathology technology
– How pathology is perceived by the public and in government as well as how developments in pathology technology are followed and understood
– Observations in the Strengthening Medicare Taskforce ReportIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
-
ICTD: Why negative results in clinical trials matter
To mark International Clinical Trials Day 2026, Australian Health Journal commences a 4 part special series leaving up to 20th May. Through conversations with leading researchers, clinicians and trial organisations, the series highlights achievements in the year that was for clinical trials.
Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.
